Actionable news
All posts from Actionable news
Actionable news in MRK: MERCK & CO. Inc,

Here's What to Expect When Merck (MRK) Releases its Latest Earnings

NEW YORK (TheStreet) -- Merck & Co. (MRK - Get Report) is scheduled to release its third fiscal 2015 earnings results on Tuesday before the opening bell.

Both profit and revenue is projected to increase slightly from a year ago.

For the latest quarter, analysts are expecting the drug maker to earn 91 cents a share on revenue of $10.8 billion.

Exclusive Look Inside: You see Jim Cramer on TV. Now, see where he invests his money. Check out his multi-million dollar portfolio and discover which stocks he is trading. Click here to see the holdings for 14-days FREE.

Earnings for the third quarter of 2014 came in at 90 cents a share and revenue came in at $10.6 billion.

The company's Keytruda drug, which has been approved to treat melanoma and lung cancer, is competing with Bristol-Myers Squibb's (BMY) Opdivo.

Analysts are estimating Keytruda sales to be around $164 million for the latest quarter.